ArticleScientific reports2026
Circulating tRF-Gly-GCC as a biomarker for colorectal cancer and Crohn's disease activity.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Distinguishing intestinal inflammation from colorectal cancer remains challenging using non-invasive biomarkers. tRNA-derived fragments have been implicated in cancer, but their role in Crohn's disease activity and their ability to differentiate inflammatory from malignant intestinal conditions remain unclear. This study evaluated circulating tRF-Gly-GCC in patients with active Crohn's disease (n = 20), inactive Crohn's disease (n = 20), colorectal cancer (n = 24), and healthy controls (n = 21). Serum tRF-Gly-GCC expression levels showed a directional increase across disease states, from controls to inactive Crohn's disease, active disease, and colorectal cancer. A Jonckheere-Terpstra test formally confirmed a significant monotonic increase (z = 7.896, p < 0.001). The marker distinguished colorectal cancer from controls with high sensitivity (95.8%) and specificity (95.2%), and differentiated colorectal cancer from Crohn's disease with sensitivity of 95.8% and specificity of 80.0%. It also distinguished active from inactive Crohn's disease with 90% sensitivity and 90% specificity. In Crohn's disease, tRF-Gly-GCC correlated with disease activity indices but not with fecal calprotectin. These findings suggest that circulating tRF-Gly-GCC reflects intestinal inflammatory activity and may serve as a non-invasive biomarker for disease assessment and differentiation between inflammatory and malignant conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.